MX2018009368A - Biomarcadores para copanlisib. - Google Patents
Biomarcadores para copanlisib.Info
- Publication number
- MX2018009368A MX2018009368A MX2018009368A MX2018009368A MX2018009368A MX 2018009368 A MX2018009368 A MX 2018009368A MX 2018009368 A MX2018009368 A MX 2018009368A MX 2018009368 A MX2018009368 A MX 2018009368A MX 2018009368 A MX2018009368 A MX 2018009368A
- Authority
- MX
- Mexico
- Prior art keywords
- biomarkers
- patients
- copanlisib
- response
- nhls
- Prior art date
Links
- 239000000090 biomarker Substances 0.000 title abstract 2
- PZBCKZWLPGJMAO-UHFFFAOYSA-N copanlisib Chemical compound C1=CC=2C3=NCCN3C(NC(=O)C=3C=NC(N)=NC=3)=NC=2C(OC)=C1OCCCN1CCOCC1 PZBCKZWLPGJMAO-UHFFFAOYSA-N 0.000 title abstract 2
- 229950002550 copanlisib Drugs 0.000 title abstract 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 abstract 2
- 230000004083 survival effect Effects 0.000 abstract 2
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091007960 PI3Ks Proteins 0.000 abstract 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 abstract 1
- 238000011223 gene expression profiling Methods 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000092 prognostic biomarker Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Evolutionary Biology (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Theoretical Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención proporciona biomarcadores que se basan en los perfiles de expresión génica los cuales pueden discriminar entre pacientes quienes responden al tratamiento con copanlisib y/o con supervivencia más larga libre de progresión y pacientes quienes no responden al tratamiento con copanlisib y/o con supervivencia más corta libre de progresión en linfoma que incluye LNH indolente y agresivo y LLC. La presente invención se refiere al uso de genes de los procesos del BCR, PI3K, NFkB, IL6, inflamación y estromales como biomarcadores predictivos de diversos cánceres humanos que incluyen, entre otros, los LNH.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662289713P | 2016-02-01 | 2016-02-01 | |
| US201662376017P | 2016-08-17 | 2016-08-17 | |
| PCT/EP2017/051903 WO2017134000A1 (en) | 2016-02-01 | 2017-01-30 | Copanlisib biomarkers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018009368A true MX2018009368A (es) | 2018-09-05 |
Family
ID=57984901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018009368A MX2018009368A (es) | 2016-02-01 | 2017-01-30 | Biomarcadores para copanlisib. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20190038632A1 (es) |
| EP (1) | EP3411497A1 (es) |
| JP (1) | JP2019511204A (es) |
| KR (1) | KR20180101603A (es) |
| CN (1) | CN108884496A (es) |
| AU (1) | AU2017214230A1 (es) |
| BR (1) | BR112018015782A2 (es) |
| CA (1) | CA3012890A1 (es) |
| CL (1) | CL2018002069A1 (es) |
| MA (1) | MA43957A (es) |
| MX (1) | MX2018009368A (es) |
| PH (1) | PH12018501623A1 (es) |
| SG (2) | SG11201806274SA (es) |
| SV (1) | SV2018005730A (es) |
| TN (1) | TN2018000271A1 (es) |
| WO (1) | WO2017134000A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3018127A1 (en) | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
| CN107864625B (zh) | 2015-03-09 | 2021-05-28 | 拜耳制药股份公司 | 含有取代的2,3-二氢咪唑并[1,2-c]喹唑啉的组合产品 |
| CA3016584A1 (en) | 2016-03-08 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | 2-amino-n-[7-methoxy-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamides |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| CN109729716B (zh) | 2016-09-23 | 2022-03-15 | 拜耳制药股份公司 | Pi3k-抑制剂的组合产品 |
| EP3645005A1 (en) | 2017-06-28 | 2020-05-06 | Bayer Consumer Care AG | Combination of a pi3k-inhibitor with an androgen receptor antagonist |
| PE20200958A1 (es) * | 2017-09-08 | 2020-09-24 | Bayer Consumer Care Ag | Solido liofilizado de copanlisib |
| WO2020092860A1 (en) * | 2018-11-01 | 2020-05-07 | The Jackson Laboratory | Gastric cancer treatments |
| EP4231872A4 (en) | 2020-10-21 | 2024-11-27 | Black Jet Innovations, Inc. | HANDLE AND STAND FOR A MOBILE DEVICE |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| EP2508525A1 (en) | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
| UA119537C2 (uk) * | 2013-04-08 | 2019-07-10 | Байєр Фарма Акцієнгезелльшафт | ЗАСТОСУВАННЯ ЗАМІЩЕНИХ 2,3-ДИГІДРОІМІДАЗО[1,2-c]ХІНАЗОЛІНІВ ДЛЯ ЛІКУВАННЯ ЛІМФОМ |
| TW201819923A (zh) * | 2013-06-20 | 2018-06-01 | 日商大鵬藥品工業股份有限公司 | 基於ＰＨＬＤＡ１或ＰＩＫ３Ｃ２Ｂ表現之ＰＩＫ３／ＡＫＴ／ｍＴＯＲ抑制劑之治療效果的預測方法 |
| SG10201807838SA (en) * | 2014-03-11 | 2018-10-30 | Council Queensland Inst Medical Res | Determining cancer aggressiveness, prognosis and responsiveness to treatment |
| US20150320754A1 (en) * | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| CN105130997B (zh) * | 2015-09-25 | 2017-12-05 | 苏州明锐医药科技有限公司 | 一种库潘尼西的制备方法 |
| CN105130998B (zh) * | 2015-09-25 | 2017-07-28 | 苏州立新制药有限公司 | 库潘尼西的制备方法 |
-
2017
- 2017-01-30 BR BR112018015782A patent/BR112018015782A2/pt not_active IP Right Cessation
- 2017-01-30 MX MX2018009368A patent/MX2018009368A/es unknown
- 2017-01-30 KR KR1020187024847A patent/KR20180101603A/ko not_active Withdrawn
- 2017-01-30 CN CN201780020013.7A patent/CN108884496A/zh active Pending
- 2017-01-30 SG SG11201806274SA patent/SG11201806274SA/en unknown
- 2017-01-30 JP JP2018539820A patent/JP2019511204A/ja active Pending
- 2017-01-30 MA MA043957A patent/MA43957A/fr unknown
- 2017-01-30 SG SG10202007262PA patent/SG10202007262PA/en unknown
- 2017-01-30 AU AU2017214230A patent/AU2017214230A1/en not_active Abandoned
- 2017-01-30 WO PCT/EP2017/051903 patent/WO2017134000A1/en not_active Ceased
- 2017-01-30 TN TNP/2018/000271A patent/TN2018000271A1/en unknown
- 2017-01-30 EP EP17703683.7A patent/EP3411497A1/en not_active Withdrawn
- 2017-01-30 US US16/074,728 patent/US20190038632A1/en not_active Abandoned
- 2017-01-30 CA CA3012890A patent/CA3012890A1/en not_active Abandoned
-
2018
- 2018-07-31 PH PH12018501623A patent/PH12018501623A1/en unknown
- 2018-08-01 CL CL2018002069A patent/CL2018002069A1/es unknown
- 2018-08-07 SV SV2018005730A patent/SV2018005730A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TN2018000271A1 (en) | 2020-01-16 |
| MA43957A (fr) | 2018-12-12 |
| SG11201806274SA (en) | 2018-08-30 |
| CL2018002069A1 (es) | 2018-11-16 |
| JP2019511204A (ja) | 2019-04-25 |
| BR112018015782A2 (pt) | 2019-01-02 |
| CN108884496A (zh) | 2018-11-23 |
| EP3411497A1 (en) | 2018-12-12 |
| KR20180101603A (ko) | 2018-09-12 |
| SG10202007262PA (en) | 2020-09-29 |
| AU2017214230A1 (en) | 2018-08-09 |
| PH12018501623A1 (en) | 2019-06-03 |
| CA3012890A1 (en) | 2017-08-10 |
| SV2018005730A (es) | 2018-12-05 |
| WO2017134000A1 (en) | 2017-08-10 |
| US20190038632A1 (en) | 2019-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018501623A1 (en) | Copanlisib biomarkers | |
| PH12018501622A1 (en) | Copanlisib biomarkers | |
| CY1123603T1 (el) | Αγωγη κακοηθειων β-κυτταρων μεσω συνδυασμου jak και ρι3κ αναστολεα | |
| CY1125588T1 (el) | Θεραπευτικοι συνδυασμοι ενος αναστολεα βτκ και ενος αναστολεα bcl-2 | |
| JOP20200192A1 (ar) | أجسام مضادة لـ tigit | |
| MX2017014736A (es) | Metodos terapeuticos y diagnosticos para cancer. | |
| WO2014144121A3 (en) | Classification and actionability indices for lung cancer | |
| MX2017008421A (es) | Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga. | |
| NZ720626A (en) | Triaging of patients having asymptomatic hematuria using genotypic and phenotypic biomarkers | |
| MX2017000840A (es) | Metodo para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cancer. | |
| EA201790549A1 (ru) | Предиктивные и прогностические биомаркеры, связанные с антиангиогенной терапией злокачественной опухоли | |
| HUE047540T2 (hu) | Javított allogén dendritikus sejtek rák kezelésében történõ alkalmazásra | |
| BR112016026730A2 (pt) | métodos de caracterização e tratamento de leucemia mieloide aguda | |
| MX2017006075A (es) | Biomarcadores para la progresion de enfermedades en melanoma. | |
| CL2017001487A1 (es) | Uso de los inhibidores de pan fgfr y método para identificación de pacientes con cáncer elegibles para el tratamiento con un inhibidor de pan fgfr. | |
| MX2017007676A (es) | Nuevos compuestos. | |
| MX394077B (es) | Metodos para tratar cancer con inhibidores de farnesiltransferasa. | |
| MX2015012063A (es) | Oligonucleotidos antisentido para el tratamiento de celulas madre del cancer. | |
| MX2016010948A (es) | Composiciones y metodos para identificar neoplasias de celulas b sensibles a terapia de reduccion de celulas b. | |
| ES2640524A1 (es) | Uso de tcfl5/cha como nuevo marcador para el pronóstico y/o diagnóstico diferencial de leucemias linfoblásticas agudas | |
| CL2015003771A1 (es) | Método ex vivo pronóstico y predictivo de respuesta de un cáncer al tratamiento con un agente antitumoral | |
| TWD184963S (zh) | 拋棄式尿布 | |
| EA201892645A1 (ru) | Проникающие в опухоль лимфоциты для адоптивной клеточной терапии | |
| PL413907A1 (pl) | Sposób wykrywania genetycznie uwarunkowanej zwiększonej predyspozycji do raka jelita grubego | |
| AR104791A1 (es) | Métodos terapéuticos y diagnósticos para el cáncer |